Dermatomyositis with anti-TIF1-γ antibodies

BMJ Case Rep. 2018 Oct 7:2018:bcr2018227574. doi: 10.1136/bcr-2018-227574.
No abstract available

Keywords: dermatology; general practice / family medicine.

Publication types

  • Case Reports

MeSH terms

  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / therapeutic use
  • Autoantibodies / blood*
  • Autoantibodies / immunology
  • Dermatomyositis / diagnosis
  • Dermatomyositis / drug therapy
  • Dermatomyositis / immunology*
  • Dermatomyositis / pathology*
  • Drug Eruptions / diagnosis
  • Drug Eruptions / etiology
  • Drug Eruptions / pathology
  • Early Detection of Cancer / standards
  • Electromyography / methods
  • Erythema / diagnosis
  • Erythema / etiology
  • Erythema / pathology
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Methotrexate / administration & dosage
  • Methotrexate / therapeutic use
  • Methylprednisolone / administration & dosage
  • Methylprednisolone / therapeutic use
  • Middle Aged
  • Skin / pathology*
  • Tacrolimus / administration & dosage
  • Tacrolimus / therapeutic use
  • Transcription Factors / antagonists & inhibitors*
  • Transcription Factors / immunology
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Autoantibodies
  • Immunosuppressive Agents
  • TRIM33 protein, human
  • Transcription Factors
  • Tacrolimus
  • Methylprednisolone
  • Methotrexate